linjc16/ctgov huggingface dataset:
Initial Combination of Gemigliptin and Metformin on Microbiota Change

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate gut microbiota change and glucose lowering effect of initial combination therapy of gemigliptin and metformin compared to glimepiride and metformin in obese patients with type 2 diabetes.

Detailed Description
-----------------
Obese type 2 diabetes patients who were not treated with anti-diabetic medication within 6 weeks, were randomly assigned to gemigliptin/metformin or sulphonylurea/metformin. After 24 week treatment, gut microbiota composition change, glucose lowering effect, body weight, and gut hormones were compared between two groups.

Official Title
-----------------
Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study)

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Drug: gemigliptin/metformin
* Drug: glimepiride/metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes Drug naive (no anti-diabetic medication within 6 weeks) HbA1c >= 7.5% BMI >= 25.0 kg/m2 Exclusion Criteria: Type 1 diabetes DKA, HHS history of hypersensitivity to sulphonylurea, metformin or DPP-4 inhibitor Gestational diabetes mellitus Serum Cr >1.5 mg/dL (male), >1.4mg/dL (female) Abnormal liver function test Anti-obesity medication within 3 months Gastrointestinal motility drug, laxatives within 3 months History of major gastrointestinal surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: gemigliptin/metformin<br>zemimet-SR 50/1000 mg x 1 tablet | Drug: gemigliptin/metformin<br>* zemimet-SR 50/1000 mg x 1 tablet<br>* Other names: Zemimet;|
| Active Comparator: glimepiride/metformin<br>amaryl-Mex 1/500 mg x 2 tablets | Drug: glimepiride/metformin<br>* amaryl-Mex 1/500 mg x 2 tablets<br>* Other names: Amarylmex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gut microbiota composition change from baseline | Analysis of gut microbiota composition at class, genus, and species levels before and after treatment. Inter-individual changes of gut microbiota changes were analyzed. | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c change | HbA1c change from baseline to 24 weeks | 24 weeks |
Low Level Light Therapy (LLLT) for Hair Growth

Study Overview
=================
Brief Summary
-----------------
A total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat. Each treatment will be 30 min per session applied on every other day for 14 weeks.

Official Title
-----------------
The Efficacy of Visible Red Light for Promoting the Growth of Human Scalp Hair for Both Male and Female - An Open-label Study

Conditions
-----------------
Male Pattern Baldness, Female Pattern Baldness

Intervention / Treatment
-----------------
* Device: low-level laser/light therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects between the ages of 18 and 60 years Diagnosed AGA in the past 12 months for male (Fitzpatrick I-IV, Hamilton-Norwood IIa-V ) and female (Fitzpatrick I-IV, and Ludwig-Savin Baldness Scale I-2, I-3, I-4, II-1, II-2 baldness patterns) Exclusion Criteria: Known Photosensitivity Using any oral or topical substance for hair growth Having Tattoo, hair transplantation, scalp reduction, malignancy or hair weave in the scalp are with alopecia Known medical conditions that could negatively affect hair growth, such as infections, connective tissue disease Currently or plan to be on a calorie-restricted diet during study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Arm<br>62 participants shall be enrolled | Device: low-level laser/light therapy<br>* Participants will wear light therapy devices for 14 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hair Density | Individual participant's hair density will be measured at the end of 14 weeks and compared with the baseline density measure at the start of the treatment. | 14 weeks | 
| Hair Density | Mean hair density for the participants after 14 weeks will be compiled and compared with the mean density of the participants' at the start of the study to determine changes. | 14 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hair Follicle Change | Both individual and all participants' follicles shall be analyzed to determine the percent of change in hair follicle anagen/telogen ratio | 14 weeks |
Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy

Study Overview
=================
Brief Summary
-----------------
The primary purpose is to compare the remifentanil requirements in deep vs moderate neuromuscular blocks during the surgical pleth index -guided anesthesia in patients undergoing laparoscopic gastrectomy.

Official Title
-----------------
Deep Versus Moderate Neuromuscular Blocks on Remifentanil Requirements in Patients Undergoing Surgical Pleth Index-guided Analgesia for Laparoscopic Gastrectomy

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: Neostigmine + glycopyrate
* Drug: Sugammadex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of gastric cancer Scheduled laparoscopic gastrectomy Exclusion Criteria: Patients refusal to consent Hyperbilirubinemia Chronic pain Opioid abuse Incurrent infective status Peripheral vascular disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Moderate NMB group<br>maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg | Drug: Neostigmine + glycopyrate<br>* maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg<br>|
| Experimental: Deep NMB group<br>maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2 4 mg/kg | Drug: Sugammadex<br>* maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total dose of remifentanil | remifentanil infusion using target effect-site concentration to achieve an surgical pleth index of range between 20 and 50 | from pneumoperitoneum to removal of laparoscope |
Analysis of Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium

Study Overview
=================
Brief Summary
-----------------
Painful bladder syndrome (PBS)/interstitial cystitis (IC) may be due to the actions of nitric oxide (NO) in the bladder tissue. NO is a gaseous substance with a very short half-life, synthesized by a group of NO-synthase-enzymes in many tissues. The goal of this study is to illuminate bladder tissue production of NO in individuals with PBS and healthy individuals, by quantification of NO and NO-enzyme expression by different molecular biological methods.

Official Title
-----------------
A Quantitative Analysis of Protein- and mRNA-Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium

Conditions
-----------------
Interstitial Cystitis, Bladder Diseases, Urinary Incontinence

Intervention / Treatment
-----------------
* Procedure: Tissue examination for protein- and mRNA-expression of NO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PBS/IC according to International Continence Society (ICS) Cystoscopy with bladder distension and deep biopsies within last 5 years Cystometry within last 5 years Normal urine culture within last month Inclusion Criteria (for control group): Benign non-invasive bladder disease No PBS/IC Normal urine culture No functional bladder disease of known nature (ex. infravesical obstruction) Exclusion Criteria: Age under 18 years Inability to understand instructions Pregnancy and lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Tissue examination for protein- and mRNA-expression of NO|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NO, mRNA-expression, pathophysiology, painful bladder syndrome
Using Technology to Promote Mental Acuity

Study Overview
=================
Brief Summary
-----------------
The study plans to test the effectiveness of behavioral economics based incentives to promote the daily use of computer programs designed to improve memory and mental acuity. Subjects will be recruited from the Pittsburgh metropolitan area. The primary objective is to determine the impact of structured financial incentives on the number of computer-based cognitive exercises completed during a 3 month intervention period.

Official Title
-----------------
Using Technology to Promote Mental Acuity

Conditions
-----------------
Mental Acuity

Intervention / Treatment
-----------------
* Behavioral: Financial incentives
* Behavioral: No incentives


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 55-80 years old Exclusion Criteria: Unable to read or understand the informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>Given access to mental exercises but receives no rewards for use. | Behavioral: No incentives<br>* Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.<br>|
| Experimental: Atomistic<br>Each individual is awarded for his or her individual participation | Behavioral: Financial incentives<br>* Participants are eligible for incentives if they participate in at least 30 games per day.<br>|
| Experimental: Altruistic<br>Participants are paired and rewarded according to the other individual's participation. | Behavioral: Financial incentives<br>* Participants are eligible for incentives if they participate in at least 30 games per day.<br>|
| Experimental: Team-based<br>Teams compete against each other and receive rewards according to relative participation. | Behavioral: Financial incentives<br>* Participants are eligible for incentives if they participate in at least 30 games per day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of activities completed | The number of memory and cognition enhancement activities played per day using the study provided software will be measured. | 6 weeks | 
| Performance on activities completed | Performance is measured by a scoring algorithm designed to estimate levels of memory, attention, cognitive control and processing speed. | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Senior citizens, mental acuity, memory
Progression of Hematopoietic Diseases in Shanghai, China

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

Detailed Description
-----------------
The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

Official Title
-----------------
Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

Conditions
-----------------
Hematologic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women 18 years or older Diagnosis of hematologic abnormality Exclusion Criteria: Children Non hematologic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Blood disease patients<br>People with blood diseases presenting at Shanghai hospitals | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood diseases presenting at Shanghai hospitals | characterization of people with blood diseases presenting at Shanghai hospitals | hospital stay | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aplastic anemia, myelodysplastic syndromes, cytopenias, acute myeloid leukemia, myelodysplastic/myeloproliferative diseases, benzene poisoning
Functional, Dynamic, and Anatomic MR Urography

Study Overview
=================
Brief Summary
-----------------
This is a clinical feasibility study to assess the value of MR imaging for obtaining functional, dynamic and anatomical information in a comprehensive imaging protocol in subjects having obstructive uropathy.

Official Title
-----------------
Functional, Dynamic, and Anatomic MR Urography

Conditions
-----------------
Hydronephrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females 18 years of age or older. All female patients of childbearing potential must agree to use a medically accepted method of contraception at the time of the study. Patients must have the ability to understand the requirements of the study, provide written and informed consent to participate, and agree to abide by the study requirements. Patients who have known or suspected hydronephrosis or patients with solitary kidneys. Exclusion Criteria: Patients with known or suspected hypersensitivity to gadolinium-based agents. Patients who are pregnant or lactating. Patients with a condition that is a contraindication to MRI (e.g., cardiac pacemaker, epicardial pacemaker leads, cochlear implants, ferromagnetic aneurysm clip, ferromagnetic halo device, or other conditions that would preclude patient proximity to a strong external magnetic field). Patients with a recent history of hemolytic anemia, sickle cell anemia or other hemoglobinopathy. Patients with a history of significant claustrophobia. Patients with impaired renal function based on 24-hr urine collection (creatinine clearance <10 ml/min or serum creatinine >1.8 mg/dl)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with two kidneys | |
| 2<br>Patients with solitary kidney | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hydronephrosis
Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome

Study Overview
=================
Brief Summary
-----------------
To prospectively investigate the effect of transjugular intrahepatic portosystemic shunt (TIPS) on oxygenation in cirrhotic patients with hepatopulmonary syndrome (HPS).

Official Title
-----------------
Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome

Conditions
-----------------
Hepatopulmonary Syndrome

Intervention / Treatment
-----------------
* Procedure: Transjugular intrahepatic portosystemic shunt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of cirrhosis Alveolar-arterial oxygen gradient ≥ 15 mm Hg (≥ 20 mm Hg for age > 64 years) Positive contrast-enhanced echocardiography Exclusion Criteria: Age of less than 18 years Intrinsic cardiopulmonary disease Malignancy Active infection Pregnancy Previous shunt therapy Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HPS-TIPS group<br> | Procedure: Transjugular intrahepatic portosystemic shunt<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alveolar-arterial oxygen gradient (PA-a,O2) |  | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macroaggregated albumin (MAA) shunt fraction |  | 12 Weeks | 
| Exhaled nitric oxide (eNO) |  | 12 Weeks |
Cannulation of the Artery Axiliaris for Extracorporeal Circulation

Study Overview
=================
Brief Summary
-----------------
Comparision of two different cannulation techniques on the neurological outcome in cardiac surcical procedures. Study hypothesis: Cannulation of the axilaris artery can reduce neurolocical side effects.

Official Title
-----------------
Cannulation of the Artery Axiliaris for Extracorporeal Circulation

Conditions
-----------------
Neurologic Manifestations

Intervention / Treatment
-----------------
* Procedure: cannulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cardiac procedure with ecc Age 40-85 years CABG and/or valve Exclusion Criteria: Stenosis of a.subclavia

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Aortic cannulation<br>routine placement of aortic cannula | Procedure: cannulation<br>* The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)<br>* Other names: MAQUET 20, 22 and 24 Fr;|
| Active Comparator: axilaris cannulation<br>new type of cannulation | Procedure: cannulation<br>* The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)<br>* Other names: MAQUET 20, 22 and 24 Fr;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surrogat endpoint: Number of participants with change from baseline in Neurolocial events at 5th postoperative day (POD) and 3 month after operation | Neurological events were detected by:NIRO (Near-infrared spectroscopy), EEG (Electrencenphalographie), MRI (Magnet resonance imaging) and test battery (Mini mental status test, HAWIE-R) | Participants will be followed for the duration of hospital stay (5 POD) and a follow up visit 3 months after discharge |